The Motley Fool··Seena HassounaPharvaris Director's Stock Sale Pales Against Upcoming Clinical Catalysts
Pharvaris director's modest 1.80% stock sale matters less than upcoming Phase 3 data and FDA submission catalysts arriving in 2026.
PHVSclinical-stage biotechPhase 3 trial